Formulary Review of 2 New Biologic Agents: Tocilizumab for Rheumatoid Arthritis and Ustekinumab for Plaque Psoriasis

BACKGROUND: Two autoimmune biologics were recently approved by the FDA: ustekinumab in September 2009 for the treatment of moderate to severe plaque psoriasis in adults who are candidates for phototherapy or systemic therapy and tocilizumab in January 2010 for adult patients with moderate to severe...

Descripción completa

Detalles Bibliográficos
Autores principales: Schafer, Jeremy A., Kjesbo, Nicole K., Gleason, Patrick P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2010
Materias:
Formulary Management
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437992/
https://www.ncbi.nlm.nih.gov/pubmed/20635831
http://dx.doi.org/10.18553/jmcp.2010.16.6.402

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437992/
https://www.ncbi.nlm.nih.gov/pubmed/20635831
http://dx.doi.org/10.18553/jmcp.2010.16.6.402

Ejemplares similares